Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of FCF Margin data on file, last reported at 72.78% in Q1 2026.

• On a quarterly basis, FCF Margin rose 5029.0% year-over-year to 72.78% in Q1 2026; TTM through Mar 2026 was 55.06%, a 2866.0% increase from a year earlier, with the FY2025 full-year figure at 61.17%, up 2635.0% from the prior year.
• FCF Margin for Q1 2026 stood at 72.78%, down from 45.53% in the prior quarter.
• Over the last five years, FCF Margin for RYTM reached as high as 365.81% in Q4 2022 and fell as low as 3588.72% in Q1 2022.
• Historically, FCF Margin has averaged 373.33% across 5 years, with a median of 121.26% in 2023.
• Across the five-year window, FCF Margin surged 9224842 bps in 2022 and tumbled 48707 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 365.81% in 2022, then plunged by 133 bps to 121.26% in 2023, then jumped by 57 bps to 52.6% in 2024, then rose by 13 bps to 45.53% in 2025, then sank by 60 bps to 72.78% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 72.78% in Q1 2026, 45.53% in Q4 2025, and 62.12% in Q3 2025.